Visual summary
Persistent kidney abnormalities merit explanation, even when the usual systemic clues are absent.
Text version
Take persistent urine findings seriously
Repeated microscopic hematuria, proteinuria, or worsening kidney function deserves a structured evaluation. Confirm collection quality, exclude common causes, and follow the trajectory rather than dismissing a persistent signal.
Serology informs probability
ANA, anti-dsDNA, and complement help assess autoimmune disease, but no single test should be interpreted outside the clinical and pathological context. Classification criteria and bedside diagnosis serve different purposes.
Quantify and trend protein
Albumin and total protein measurements answer related but different questions. Repeat unexpected results and use consistent units and methods when evaluating progression or treatment response.
Let persistent renal findings drive evaluation
Quantified proteinuria, active sediment, or otherwise unexplained loss of kidney function can justify a biopsy discussion even when anti-dsDNA or complement is not striking. Biopsy distinguishes activity, chronic damage, and competing lesions; it also prevents serologic reassurance from delaying renal assessment.
Match treatment to disease
Treatment depends on histologic class, activity, chronic damage, kidney function, comorbidities, and goals. Kidney failure changes eligibility and risk; specialist review is essential.
Do not turn subgroup results into exclusions
When selecting an add-on therapy, use guideline recommendations, labeling, renal function, and the actual trial population. An exploratory proteinuria subgroup is not a universal contraindication, nor proof that another active drug is superior. Reassess the clinical and urine response before escalating for presumed treatment failure.